Semaglutide and diabetic retinopathy: bring the eye history into the decision

A semaglutide treatment discussion should include an existing history of diabetic eye disease. The reason is a specific signal in a diabetes trial, followed by analyses exploring who was most affected. It should be discussed without implying that every user will develop eye damage or that the signal can be dismissed.

What SUSTAIN 6 reported

In SUSTAIN 6, retinopathy complications were more frequent with semaglutide than placebo, with a hazard ratio of 1.76 and a 95% confidence interval of 1.11 to 2.78. The defined complications included serious retinal events and treatments. See the primary trial report.

A hazard ratio is a relative comparison under study conditions. It does not tell an individual their personal probability, and it should not be presented as an absolute percentage-point increase.

Exploratory explanations remain explanations

A subsequent post hoc analysis suggested that much of the signal might relate to the magnitude and rapidity of early HbA1c reduction in people with pre-existing retinopathy, poorer initial glucose control and insulin treatment. The analysis also reported no similar imbalance across several other SUSTAIN trials.

This helps refine the clinical question, but a post hoc analysis does not prove a complete causal explanation. It should neither erase the original signal nor be generalized to every patient or product.

Make the eye history available

Bring the latest eye assessment you have, any diagnosis of retinopathy and previous retinal treatments to the consultation. Ask who will coordinate care if diabetes treatment changes and what follow-up is appropriate for the existing eye condition.

The current Wegovy label specifically calls for monitoring patients with a history of diabetic retinopathy. The details of an individual follow-up plan belong to the treating clinicians.

Do not adjust treatment from a headline

Concern about a trial signal is a reason for a better-informed review, not an instruction to stop a prescribed medicine independently. Ask how glucose-related goals, eye history and other benefits or risks are being weighed together.

Likewise, this evidence does not establish that a different route, salt form or compounded preparation avoids the concern. The useful decision is coordinated assessment of the actual product and the person’s eye-health context.

Keep the dates of eye findings and diabetes-treatment changes in the same record. That timeline can support communication between clinicians without asking the patient to decide independently what caused a change.